



health in code

illumina®



TECHNICAL SECRETARIAT

Maika Romero Fernández,
Telf: 981 900 700 - ext. 103, Mobil: 669 403 807,
maikaromero@orzancongres.com, Skype: maika.romero2
Orzán Congres, S.L. , www.orzancongres.com

VENUE

Museo Nacional de Ciencia y Tecnología (MUNCYT).
Plaza del Museo Nacional, 1;
15011 A Coruña, Spain. Tel: 900 100 134

SPEAKERS

Prof. William J. McKenna.

Program Director - Cardiovascular, UCL Partners, Institute of Cardiovascular Science University College London, UK.

Prof. Perry Elliot.

Clinical Director Inherited Cardiac Disease Unit, The Heart Hospital, London, UK

Luis Rocha Lopes, MD.

Research Fellow, Institute of Cardiovascular Science (London); Cardiology Department, Hospital Garcia de Orta, Almada, Portugal.

Prof. Jens Mogensen.

Department of Cardiology, Odense University Hospital, Denmark.

Niall Mahon, MD.

Consultant Cardiologist, Mater Misericordiae University Hospital, Dublin, Ireland.

Michael Arad, MD.

Senior Lecturer in Cardiology, Cardiomyopathy Clinic and Heart Failure Service, Leviev Heart Institute, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Israel.

Aris Anastasakis, MD.

Consultant Cardiologist, Scientific Supervisor 1st Dpt of Cardiology, University of Athens, Greece.

Jean-Charles Hoda.

CEO SwissCheckUp SA, Geneva, Switzerland.

Nicola Marziliano, PhD.

Research Geneticist at the Cardiovascular Department in Azienda Ospedaliero Universitaria, Parma; Research Geneticist and Editor in Ospedale Cà Granda Niguarda, Milano, Italy.

Pablo García-Pavía, MD.

Heart Failure and Cardiomyopathy Unit Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Tomás Ripoll, MD.

Cardiology Service, Inherited Cardiovascular Diseases Unit Coordinator in Hospital Son Llatzer, Palma de Mallorca, Spain.

Juan R. Gimeno, MD.

Cardiology Department, Inherited Cardiovascular Diseases Unit Coordinator in Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.

Juan Jiménez-Jáimez, MD.

Cardiology Service, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.

Ian Paterson.

Genzyme, EMEA region, Sr. Brand Director, Fabrazyme & Myozyme, Amsterdam/Madrid

Martin Ortiz-Genga, MD.

Research Group on Inherited Cardiovascular Diseases, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

Diego Alonso-García, MD.

Research Group on Inherited Cardiovascular Diseases, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

Roberto Barriales-Villa, MD.

Fundación Profesor Novoa Santos, Research Group on Inherited Cardiovascular Diseases, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

Lorenzo Monserrat, MD.

Coordinator of the National Reference Unit for Inherited Cardiovascular Diseases in Complejo Hospitalario Universitario A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

GENETICS IN INHERITED CARDIOVASCULAR DISEASES AND SUDDEN DEATH PREVENTION

Perspectives for the clinical application
of Next Generation Sequencing

/ A CORUÑA / 2nd DECEMBER 2013 / MUNCYT



Xerencia Xestión Integrada
A Coruña



UNIVERSIDADE DA CORUÑA

MAIN OBJECTIVES

To share knowledge and experiences about the present situation, impact and application of Next Generation Sequencing (NGS) in inherited cardiovascular diseases.

METHODOLOGY

Each topic is introduced by several brief presentations that should serve as basis for the participation of the audience in the following discussion.

ORGANIZERS

Grupo de Investigación Cardiovascular, Universidad de A Coruña (GRINCAR-UDC) and Instituto de Investigación Biomédica de A Coruña (INIBIC); Cardiology Service, Complejo Hospitalario Universitario de A Coruña (CHUAC); Red de Investigación Cardiovascular (RIC).

PROGRAM

Introduction and welcome

8.20 | 8.30

Ricardo Cao-Abad | Vice-Chancellor of the University of A Coruña

José Manuel Vázquez-Rodríguez, MD | Innovation and Research Director of the Complejo Hospitalario Universitario A Coruña (CHUAC)

Prof. Alfonso Castro-Beiras | Director of the Heart Unit and Head of the Cardiology Department at Complejo Hospitalario Universitario A Coruña (CHUAC)

Presentation of the meeting

8.30 | 8.40

Lorenzo Monserrat

Introductory lecture

8.40 | 9.00

Genetic studies in cardiovascular diseases.
William J McKenna

Introduction to NGS technology (focused on DNA analysis)

Moderators: *Nicola Marziliano, Diego García.*

9.00 | 10.00

Principles of NGS: What is it and how does it work? Sample preparation, capture/amplicons and sequencing.
Illumina presentation

10.00 | 10.15

Questions/Discussion (to be continued during the following topics).

Our experiences: research in inherited cardiovascular diseases:

Moderators: *Jens Mogensen, Roberto Barriales-Villa.*

10.15 | 10.25

NGS in Hypertrophic cardiomyopathy.
Luis Lopes

10.25 | 10.35

NGS in Dilated cardiomyopathy.
Pablo García-Pavía

10.35 | 10.45

NGS in Idiopathic Ventricular Fibrillation.
Juan Jiménez-Jáimez

10.45 | 11.15

Discussion: Is this the correct direction? Could it be done in a different way? Other experiences? What's next?...

11.15 | 11.45 ☕

Coffee break.

From research to clinical application

Moderators: *Aris Anastasakis, Perry Elliott.*

11.45 | 11.55

Presenting the problems-challenges (what technology, what strategy, who decides, the interpretation, etc.).
Martin Ortiz-Genga

11.55 | 12.05

What genetics do we need (and may we afford) in a reference unit: genes-panels-exomes? Clinician's perspective.
Juan Ramón Gimeno

12.05 | 12.15

Will/should/could the patient decide? What are my patients demanding?.
Michael Arad

12.15 | 12.25

The problem of incidental findings.
Jens Mogensen

12.25 | 13.00

Discussion: Individual genes/focused panels/big panels/exomes/ genomes/all of them? Do we agree with the American Board of Medical Genetics Recommendations for the management of incidental findings?...

Science, politics and economy: knowledge, power and money

Moderators: *Tomás Ripoll, Michael Arad*

13.00 | 13.10

What would the European WG on Myocardial and Pericardial Diseases recommend about the application of NGS technologies?.
Perry Elliott

13.10 | 13.20

Who controls the indications?, and the delivery of the results? (Cardiologists, genetic counselors and managers).
Niall Mahon

13.20 | 13.30

Reimbursement for genetic studies. What is the situation?.
Jean-Charles Hoda

13.30 | 13.40

NGS in cardiovascular diseases and the pharmaceutical companies.
Ian Paterson

13.40 | 14.05

Discussion.

“Next Generation Sequencing” Perspectives

14.05 | 14.25

Lorenzo Monserrat

Closing remarks

14.25 | 14.30

William J McKenna, Lorenzo Monserrat

Lunch

14.30 | 15.30 🍴